Shares of OpGen Inc (NASDAQ:OPGN) hit a new 52-week low on Friday . The stock traded as low as $3.65 and last traded at $0.15, with a volume of 2114500 shares. The stock had previously closed at $0.17.
Several analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of OpGen in a research note on Tuesday, October 24th. Zacks Investment Research raised shares of OpGen from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a research note on Tuesday, November 14th.
The firm has a market cap of $4,010.00 and a P/E ratio of -0.26. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 1.13.
An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. bought a new stake in OpGen Inc (NASDAQ:OPGN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned 2.72% of OpGen as of its most recent SEC filing. 11.83% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3148264/opgen-opgn-sets-new-52-week-low-at-3-65.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.